Asia Pacific Menopausal Disorder Treatment Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 2,026.59 Million |
 Market Size (Forecast Year) |
USD 4,097.76 Million |
 CAGR |
% |
| Major Markets Players |
Asia-Pacific Menopausal Disorder Treatment Market, By Stages (Menopause, Postmenopause, Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression, Others), Dosage Form (Tablet, Creams, Gels, Rings/Insert, Patch/Film, Injection Shot, Spray, Others), Route of Administration (Oral, Vaginal, Transdermal, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Menopause is one of the most physically demanding times in a women’s life, prompting worldwide pharmaceutical companies to create effective medications to treat it and related problems. Menopause, also known as the climatic period, occurs when a woman’s menstrual periods stop occurring permanently. Numerous significant changes occur in the female body during this time, resulting in the emergence of several illnesses. Menopausal problems are becoming more common in all parts of the world, and healthcare organizations support the development and use of medications that can effectively treat them. It also has prompted pharmaceutical firms to develop and market medications that alleviate the long term symptoms of menopausal illnesses in women and do not affect their health during or after treatment.
Data Bridge Market Research analyses that the Asia-Pacific menopausal disorder treatment market was valued at USD 2,026.59 million in 2021 and is expected to reach USD 4,097.76 million by 2029, registering a CAGR of 9.20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Stages (Menopause, Postmenopause, Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression, Others), Dosage Form (Tablet, Creams, Gels, Rings/Insert, Patch/Film, Injection Shot, Spray, Others), Route of Administration (Oral, Vaginal, Transdermal, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
|
Countries Covered |
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC). |
|
Market Players Covered |
Eli Lilly and Company (US), Novo Nordisk A/S (Denmark), Allergan (Ireland), Dr. Reddy’s Laboratories Ltd. (India), GlaxoSmithKline plc (UK), Mylan N.V. (US), Pfizer Inc. (US), Ipsen Pharma (France), Abbott (US), Besins Healthcare (Belgium) |
|
Market Opportunities |
|
Market Definition
Menopausal syndrome refers to the symptoms that accompany the physiological changes that occur in a woman's body when her reproductive years come to an end. Menopause is a natural female hormone deficiency that happens between the ages of 45 and 55. It is a typical result of the ageing process. The ovaries gradually become less active and produce less sex hormone throughout this time (estrogen and progesterone). As a result, menstruation is no longer possible. If a woman has not had a monthly cycle for a year and there is no underlying cause, she is usually considered menopausal.
Asia-Pacific Menopausal Disorder Treatment Market Dynamics
Drivers
- Rise in the prevalence of menopausal disorder
The rising prevalence of menopausal disorder is estimated to propel the menopausal disorder treatment market's growth. Along with this, increasing cases of hormonal therapy, radiation therapy and hysterectomy will influence the market’s growth rate.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of menopausal disorder treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness and technological advancement will expand the menopausal disorder treatment market. Additionally, high disposable income and continuously changing lifestyle will expand the menopausal disorder treatment market. Along with this, rising geriatric population and surging cases of hormone-related disorders will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the menopausal disorder treatment market growth. Along with this, rising drug approvals and launch of innovative products will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the menopausal disorder treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the hormonal therapy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the menopausal disorder treatment market. Additionally, lack of awareness and side effects of medication will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This menopausal disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the menopausal disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Menopausal disorder treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Asia-Pacific Menopausal Disorder Treatment Market
The menopausal disorder treatment market has been crippled by the COVID-19 pandemic, which has resulted in the temporary closure of manufacturing facilities and a drop in demand. While the globe tried to stop SARS-CoV-2 from spreading, leading corporations were working to strengthen their supply networks and speed up their operations in order to avoid more losses. Healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness also hampered the menopausal disorder treatment market. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the menopausal disorder treatment market is expected to recover more quickly in the coming years.
Asia-Pacific Menopausal Disorder Treatment Market Scope
The menopausal disorder treatment market is segmented on the basis of stages, type, menopause symptoms, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Stages
- Menopause
- Postmenopause
- Perimenopause
Type
- Hormonal Therapy
- Estrogen
- Progesterone
- Combination
- Non-Hormonal Therapy
- Anti-Depressants
- Others
Menopause Symptoms
- Vasomotor Symptoms
- Atrophic Vaginitis
- Osteoporosis
- Joint Pain
- Weight Gain
- Dyspareunia
- Depression
- Others
Dosage Form
- Tablet
- Creams
- Gels
- Rings/Insert
- Patch/Film
- Injection Shot
- Spray
- Others
Route of Administration
- Oral
- Vaginal
- Transdermal
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Asia-Pacific Menopausal Disorder Treatment Market Regional Analysis/Insights
The menopausal disorder treatment market is analysed and market size insights and trends are provided by country, stages, type, menopause symptoms, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Asia-Pacific menopausal disorder treatment market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Japan dominates the Asia-Pacific menopausal disorder treatment market because of the presence of major key players and surging healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Menopausal Disorder Treatment Market Share Analysis
The menopausal disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to menopausal disorder treatment market.
Some of the major players operating in the menopausal disorder treatment market are:
- Mylan N.V. (US)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Eli Lilly and Company (US)
- Abbott (US)
- Novo Nordisk A/S (Denmark)
- Allergan (Ireland)
- Dr. Reddy’s Laboratories Ltd. (India)
- Ipsen Pharma (France)
- Besins Healthcare (Belgium)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STAGES OF MENOPAUSAL DISORDER TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: REGULATIONS
6 IMPACT OF COVID-19 ON ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
6.1 PRICE IMPACT
6.2 MPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING CASES OF CHEMOTHERAPY, RADIATION THERAPY AND HYSTERECTOMY
7.1.2 GROWING CASES OF HORMONE RELATED DISORDERS IN WOMEN
7.1.3 VULNERABLE AGING POPULATION OF MENOPAUSE WOMEN
7.1.4 INCREASING ASIA-PACIFIC HEALTHCARE EXPENDITURE
7.1.5 PRESENCE OF FAVOURABLE REIMBURSEMENT
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS OF MEDICATION
7.2.2 INADEQUATE KNOWLEDGE ABOUT MENOPAUSE IN SOME DEVELOPING COUNTRIES
7.2.3 HIGH COST OF HORMONAL THERAPY
7.3 OPPORTUNITIES
7.3.1 RISING GOVERNMENT INITIATIVES TO PROMOTE WOMEN’S HEALTH
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISING AWARENESS ABOUT THE TREATMENT
7.3.4 PRESENCE OF STRONG PRODUCT PIPELINE
7.4 CHALLENGES
7.4.1 AVAILABILITY OF ALTERNATIVES
7.4.2 PATENT EXPIRY
7.4.3 SOCIAL CONCERN REGARDING MENOPAUSAL SYMPTOMS DISCUSSION
8 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES
8.1 OVERVIEW
8.2 MENOPAUSE
8.3 POSTMENOPAUSE
8.4 PERIMENOPAUSE
9 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 HORMONAL THERAPY
9.2.1 ESTROGEN
9.2.1.1β-Estradiol
9.2.1.1.1 Minivelle
9.2.1.1.2 Others
9.2.1.2 Conjugated Estrogens
9.2.1.2.1 Premarin
9.2.1.2.2 Enjuvia
9.2.1.2.3 Others
9.2.1.3 Estradiol Hemihydrate
9.2.1.3.1 Vagifem
9.2.1.3.2 Others
9.2.1.4 Esterified Estrogens
9.2.1.5 Estradiol Acetate
9.2.1.5.1 Femring
2.2.1.5.2 Others
9.2.1.6 Estropipate
9.2.1.7 Estetrol (Donesta)
9.2.2 COMBINED ESTROGENS & PROGESTOGEN DRUGS
9.2.2.1β-Estradiol (E) + Norethindrone Acetate (P)
9.2.2.1.1 Combipatch
9.2.2.1.2 Estalis
9.2.2.1.3 Others
9.2.2.2 Ethinyl Estradiol (E) + Norethindrone Acetate (P)
9.2.2.2.1 Minastrin
9.2.2.2.2 Others
9.2.2.3 Conjugated Estrogens (E) + Medroxyprogestrone Acetate (P)
9.2.2.3.1 Premphase/Prempro
9.2.2.3.2 Others
9.2.3 PROGESTOGENS
9.2.3.1 Medroxyprogesterone Acetate
9.2.3.1.1 Provera
9.2.3.1.2 Others
9.2.3.2 Micronized Progesterone
9.2.4 OTHERS
9.3 NON HORMONAL THERAPY
9.3.1 MEDICATION
9.3.1.1 Anti-Depressants
9.3.1.1.1 Brisdelle (Paroxetine)
9.3.1.1.2 Zoloft
9.3.1.1.3 Others
9.3.1.2 Ospemifene / Osphena
9.3.1.3 Gabapentin
9.3.1.4 Clonidine
9.3.1.5 Others
9.3.2 SUPPLEMENTS
9.3.2.1 Herbal Supplements
9.3.2.1.1 Ginseng
9.3.2.1.2 Ashwagandha
9.3.2.1.3 Others
9.3.2.2 Vitamin D
9.3.2.3 Others
10 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS
10.1 OVERVIEW
10.2 VASOMOTOR SYMPTOMS
10.3 ATROPHIC VAGINITS
10.4 OSTEOPOROSIS
10.5 JOINT PAIN
10.6 WEIGHT GAIN
10.7 DYSPAREUNIA
10.8 DEPRESSION
10.9 OTHERS
11 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM
11.1 OVERVIEW
11.2 TABLETS
11.3 CREAMS
11.4 GELS
11.5 RINGS/INSERTS/INSERTS
11.6 PATCH/FILMS
11.7 INJECTION SHOT
11.8 SPRAY
11.9 OTHERS
12 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 VAGINAL
12.4 TRANSDERMAL
12.5 PARENTERAL
12.5.1 SUBCUTANEOUS
12.5.2 INTRAVENOUS
12.5.3 OTHERS
13 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
14 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY GEOGRAPHY
15.1 ASIA PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 AUSTRALIA
15.1.4 INDIA
15.1.5 SOUTH KOREA
15.1.6 SINGAPORE
15.1.7 INDONESIA
15.1.8 THAILAND
15.1.9 MALAYSIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA PACIFIC
16 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 NOVARTIS AG
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 NOVO NORDISK A/S
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 MYLAN N.V.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 DR. REDDY’S LABORATORIES LTD.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ELI LILLY AND COMPANY
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 ABBOTT
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 IPSEN PHARMA
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 GLAXOSMITHKLINE PLC
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 BESINS HEALTHCARE
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 THERAPEUTICSMD, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 DUCHESNAY USA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 FERVENT PHARMACEUTICALS INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 MITHRA PHARMACEUTICALS
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 KANDY THERAPEUTICS
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SEBELA PHARMACEUTICALS
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SOJOURNIX INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 3 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES 2019-2027 (USD MILLION)
TABLE 4 ASIA-PACIFIC MENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 5 ASIA-PACIFIC POSTMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 6 ASIA-PACIFIC PERIMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 7 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2019-2027 (USD MILLION)
TABLE 8 ASIA-PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 9 ASIA-PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 10 ASIA-PACIFIC HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 11 ASIA-PACIFIC 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 12 ASIA-PACIFIC CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 13 ASIA-PACIFIC ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 14 ASIA-PACIFIC ESTRADIOL ACETATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 15 ASIA-PACIFIC HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 16 ASIA-PACIFIC 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 17 ASIA-PACIFIC ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 18 ASIA-PACIFIC CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 19 ASIA-PACIFIC HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC NON HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 22 ASIA-PACIFIC NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 23 ASIA-PACIFIC NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 24 ASIA-PACIFIC ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 27 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS 2019-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC VASOMOTOR SYMPTOMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC ATROPHIC VAGINITIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC OSTEOPOROSIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 31 ASIA-PACIFIC JOINT PAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 32 ASIA-PACIFIC WEIGHT GAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 33 ASIA-PACIFIC DYSPAREUNIA IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 34 ASIA-PACIFIC DEPRRESSION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM 2019-2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC TABLETS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC CREAMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 39 ASIA-PACIFIC GELS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 40 ASIA-PACIFIC RINGS/INSERTS/INSERTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 41 ASIA-PACIFIC PATCH/FILMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 42 ASIA-PACIFIC INJECTION SHOT IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 43 ASIA-PACIFIC SPRAY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 44 ASIA-PACIFIC OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 45 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 46 ASIA-PACIFIC ORAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 47 ASIA-PACIFIC VAGINAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 48 ASIA-PACIFIC TRANSDERMAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 49 ASIA-PACIFIC PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 50 ASIA-PACIFIC PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 51 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER 2019-2027 (USD MILLION)
TABLE 52 ASIA-PACIFIC HOSPITAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 53 ASIA-PACIFIC CLINICS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 54 ASIA-PACIFIC HOME HEALTHCARE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 55 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBITION CHANNEL, 2019-2027 (USD MILLION)
TABLE 56 ASIA-PACIFIC HOSPITAL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 57 ASIA-PACIFIC RETAIL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 58 ASIA-PACIFIC ONLINE PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 59 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 60 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 61 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 62 ASIA- PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 ASIA- PACIFIC HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 64 ASIA- PACIFIC 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 65 ASIA- PACIFIC CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 66 ASIA- PACIFIC ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 67 ASIA- PACIFIC ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 68 ASIA- PACIFIC ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 69 ASIA- PACIFIC HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 70 ASIA- PACIFIC 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 ASIA- PACIFIC ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 72 ASIA- PACIFIC CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 73 ASIA- PACIFIC HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 74 ASIA- PACIFIC MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 75 ASIA- PACIFIC NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 76 ASIA- PACIFIC NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 77 ASIA- PACIFIC ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 78 ASIA- PACIFIC NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 79 ASIA- PACIFIC HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 81 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 82 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 83 ASIA- PACIFIC PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 84 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 85 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 86 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 87 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 88 JAPAN HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 89 JAPAN HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 90 JAPAN 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 91 JAPAN CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 92 JAPAN ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 93 JAPAN ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 94 JAPAN ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 95 JAPAN HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 96 JAPAN 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 JAPAN ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 98 JAPAN CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 99 JAPAN HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 100 JAPAN MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 101 JAPAN NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 102 JAPAN NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 103 JAPAN ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 104 JAPAN NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 105 JAPAN HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 106 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 107 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 108 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 109 JAPAN PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 110 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 111 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 112 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 113 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 114 CHINA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 115 CHINA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 116 CHINA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 117 CHINA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 118 CHINA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 119 CHINA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 120 CHINA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 121 CHINA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 122 CHINA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 123 CHINA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 124 CHINA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 125 CHINA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 126 CHINA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 127 CHINA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 128 CHINA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 129 CHINA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 130 CHINA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 131 CHINA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 132 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 133 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 134 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 135 CHINA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 136 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 137 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 138 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 139 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 140 AUSTRALIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 141 AUSTRALIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 142 AUSTRALIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 143 AUSTRALIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 144 AUSTRALIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 145 AUSTRALIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 146 AUSTRALIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 147 AUSTRALIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148 AUSTRALIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 149 AUSTRALIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 150 AUSTRALIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 151 AUSTRALIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152 AUSTRALIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 153 AUSTRALIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 154 AUSTRALIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 155 AUSTRALIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 156 AUSTRALIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 157 AUSTRALIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 158 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 159 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 160 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 162 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 163 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 164 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 165 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 166 INDIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 167 INDIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 168 INDIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 169 INDIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 170 INDIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 171 INDIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172 INDIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 173 INDIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 174 INDIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 175 INDIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 176 INDIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 177 INDIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 178 INDIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 179 INDIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 180 INDIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 181 INDIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 INDIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 183 INDIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 184 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 185 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 186 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 187 INDIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 188 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 189 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 190 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 191 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 192 SOUTH KOREA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 193 SOUTH KOREA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 194 SOUTH KOREA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 195 SOUTH KOREA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 196 SOUTH KOREA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 197 SOUTH KOREA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 198 SOUTH KOREA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 199 SOUTH KOREA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 200 SOUTH KOREA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 201 SOUTH KOREA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 202 SOUTH KOREA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 203 SOUTH KOREA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 204 SOUTH KOREA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 205 SOUTH KOREA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 206 SOUTH KOREA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 207 SOUTH KOREA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 208 SOUTH KOREA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 209 SOUTH KOREA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 210 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 211 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 212 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 213 SOUTH KOREA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 214 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 215 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 216 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 217 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 218 SINGAPORE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 219 SINGAPORE HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 220 SINGAPORE 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 221 SINGAPORE CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 222 SINGAPORE ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 SINGAPORE ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 224 SINGAPORE ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 225 SINGAPORE HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 226 SINGAPORE 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 227 SINGAPORE ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 228 SINGAPORE CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 229 SINGAPORE HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 230 SINGAPORE MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 231 SINGAPORE NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 232 SINGAPORE NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 233 SINGAPORE ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 234 SINGAPORE NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 235 SINGAPORE HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 236 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 237 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 238 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 239 SINGAPORE PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 240 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 241 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 242 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 243 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 244 INDONESIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 245 INDONESIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 246 INDONESIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 247 INDONESIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 248 INDONESIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 249 INDONESIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 250 INDONESIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 251 INDONESIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 252 INDONESIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 253 INDONESIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 254 INDONESIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 255 INDONESIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 256 INDONESIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 257 INDONESIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 258 INDONESIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 259 INDONESIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 260 INDONESIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 261 INDONESIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 262 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 263 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 264 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 265 INDONESIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 266 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 267 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 268 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 269 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 270 THAILAND HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 271 THAILAND HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 272 THAILAND 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 273 THAILAND CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 274 THAILAND ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 275 THAILAND ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 276 THAILAND ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 277 THAILAND HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 278 THAILAND 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 279 THAILAND ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 280 THAILAND CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 281 THAILAND HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 282 THAILAND MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 283 THAILAND NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 284 THAILAND NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 285 THAILAND ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 286 THAILAND NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 287 THAILAND HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 288 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 289 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 290 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 291 THAILAND PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 292 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 293 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 294 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 295 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 296 THAILAND HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 297 THAILAND HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 298 THAILAND 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 299 THAILAND CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 300 THAILAND ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 301 THAILAND ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 302 THAILAND ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 303 THAILAND HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 304 THAILAND 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 305 THAILAND ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 306 THAILAND CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 307 THAILAND HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 308 THAILAND MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 309 THAILAND NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 310 THAILAND NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 311 THAILAND ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 312 THAILAND NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 313 THAILAND HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 314 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 315 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 316 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 317 THAILAND PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 318 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 319 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 320 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 321 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 322 PHILIPPINES HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 323 PHILIPPINES HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 324 PHILIPPINES 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 325 PHILIPPINES CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 326 PHILIPPINES ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 327 PHILIPPINES ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 328 PHILIPPINES ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 329 PHILIPPINES HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 330 PHILIPPINES 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 331 PHILIPPINES ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 332 PHILIPPINES CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 333 PHILIPPINES HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 334 PHILIPPINES MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 PHILIPPINES NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 336 PHILIPPINES NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 337 PHILIPPINES ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 338 PHILIPPINES NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 339 PHILIPPINES HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 340 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 341 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 342 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 343 PHILIPPINES PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 344 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 345 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 346 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 347 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 348 VIETNAM HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 349 VIETNAM HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 350 VIETNAM 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 351 VIETNAM CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 352 VIETNAM ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 353 VIETNAM ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 354 VIETNAM ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 355 VIETNAM HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 356 VIETNAM 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 357 VIETNAM ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 358 VIETNAM CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 359 VIETNAM HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 360 VIETNAM MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 361 VIETNAM NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 362 VIETNAM NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 363 VIETNAM ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 364 VIETNAM NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 365 VIETNAM HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 366 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 367 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 368 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 369 VIETNAM PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 370 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 371 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 372 REST OF ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING CASES OF HORMONE RELATED DISORDERS AND INCREASING CASES OF CHEMOTHERAPY, RADIATION THERPAY AND HYSTERECTOMY IS DRIVING THE ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 MENOPAUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
FIGURE 14 PER CAPITA HEALTHCARE EXPENDITURE IN 2018 (USD)
FIGURE 15 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, 2019
FIGURE 16 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, 2019-2027 (USD MILLION)
FIGURE 17 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, CAGR (2020-2027)
FIGURE 18 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, 2019
FIGURE 20 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 21 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 22 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, 2019
FIGURE 24 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, 2019-2027 (USD MILLION)
FIGURE 25 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, CAGR (2020-2027)
FIGURE 26 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, 2019
FIGURE 28 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, 2019-2027 (USD MILLION)
FIGURE 29 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, CAGR (2020-2027)
FIGURE 30 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 32 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 33 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 34 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, 2019
FIGURE 36 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 37 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 38 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 40 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 41 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBITION CHANNEL, CAGR (2020-2027)
FIGURE 42 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBITION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 44 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 45 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 46 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 47 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES (2020-2027)
FIGURE 48 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: COMPANY SHARE 2019 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
